Publikationsliste
Kamp M.A., Knipps J., Steiger H.J., Rapp M., Cornelius J.F., Folke-Sabel S., Sabel M.: Training for brain tumour resection: a realistic model with easy accessibility. Acta NC. 2015 Sep 26.(IF 1,52)
Ringel F., Pape H., Meyer B., Ringel F., Simon M., Sabel M., Rapp M., Krex D., Bock H.C., Rohde V., Weyerbrock A., Machein M.R., Westermaier T., Ernestus R.I., Franz K., Senft C., Schucht P., Beck J., Misch M., Vajkoczy P., Salehi M., Nievas M.C., Höllerhage H.G., Schneider T., Tapia-Perez H., Höllig A., Clusmann H., Aumann W., Kretschmer T., Seiz-Rosenhagen M., Thomé C., Buchalla R., Groß C., Stockhammer F., Radovanovic I., Schaller K., Wolf P.: Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2015 Aug 4. pii: nov145. (IF 6,77)
Kamp M., Rapp M°., Bühner J., Slotty P.J., Reichelt D., Sadat H., Dibué-Adjei M., Steiger H.J., Turowski B., Sabel M.: Early postoperative magnet resonance tomography after resection of cerebral metastases. Acta NC 2015 Sep;157(9):1573-80(IF 1,52)
Galldiks N., Stoffels G., Filss C., Rapp M., Blau T., Tscherpel C., Ceccon G., Veronika Dunkl V., Weinzierl M., Stoffel M., Sabel M., Fink G.R., Shah N.J., Langen K.-J.: The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology,May2015 (IF 5,28)
------
KampM.,Rapp M°., SlottyP.J., Turowski B., Sadat H., SmugaM., Dibué-Adjei M., Steiger H.-J. Szelényi A., Sabel M.: Incidence of local in-brain progression after supramarginal resection of cerebral metastases. Acta NC, March 2015 (IF 1,52)
Kamp M., Felsberg J., Sadat H., Kuzibaev J., Steiger H.-J.,Rapp M., Reifenberger G., Dibué M., Sabel M.: 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta NC, Feb 2015(IF 1,52)
Rapp M., Sadat H., Slotty P., Steiger H.-J., Budach W., Sabel M.: Feasibility of the EORTC/NCIC trial protocol in a neurosurgical outpatient unit: the case for Neurosurgical Neurooncology. Cen Eur Neurosurg., Apr 27, 2015(IF 0,83)
Galldiks N., Dunkl V., Stoffels G., Hutterer M., Rapp M., Sabel M., Reifenberger G., Kebir S., Dorn F., Blau T., Herrlinger U., Hau P., Ruge MI., Kocher M., Goldbrunner R., Fink GR., Drzezga A., Schmidt M., Langen KJ.: Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging., Nov 20,2014 (IF 5.217)
Hamilton J.D., Rapp M.,Schneiderhahn M., Sabel M., Hayman A., Scherer A., Kröpil P., Budach W, Kretschmar U, Arne Gerber P, Prabhu S,Ginsberg LE, Bölke E, Matuschek C.: Glioblastoma Multiforme Metastasis Outside the CNS: Three Case Reports and Possible Mechanisms of Escape. J Clin Oncol.,Feb 24, 2014 (IF 18,038)
Langen K.J., Rapp M., Galldiks N., Reifenberger G., Floeth FW.: Reply: Discriminating Ability of 18F-FET PET for Several Cerebral Neoplastic Lesions, J Nucl Med., Nov 6, 2013 (IF 6,38)
Galldiks N., Stoffels G., Ruge M., Rapp M., Sabel M., Reifenberger G., Erdem Z., Shah N., Fink G., Coenen H., Langen K.:Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma, J Nucl Med., Oct 54, 2013 (IF 6,38)
Rapp M., Kamp M., Steiger H.J., Sabel M.: Endoscopic assisted visualisation of 5-ALA induced fluorescence in malignant glioma surgery- a technical note, Jul 2013, World of Neurosurgery (IF 0,68)
Galldiks N., Rapp. M., Stoffels G., Dunkl V., Sabel M., Langen KJ.: Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F- Fluorethyl)-L-tyrosine Positron Emission Tomography in comparison with magnetic resonance imaging, Mol imaging, Aug 1;12(5) (IF 3,16)
Kamp M., Dibué M., Santacroce A., Zella S, Niemann L., Steiger H.J., Rapp M. and Sabel M.:The tumour is not enough or is it? Problems and new concepts in the surgery of cerebral metastases, ecancer Apr., 7:306, 2013
Rapp M., Goeppert M., Felsberg J., Steiger HJ., Sabel M.: The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma- a single centre retrospective study, British J Neurosurg (IF 0,88)
Rapp M., Floeth F., Steiger H.J., Sabel M., Langen K.J, Galldiks N.: Clinical Value of 18F-Fluoroethyl-L-Tyrosine Positron- Emission Tomography (FET PET) in Low-Grade Glioma - Neurosurg Focus, Feb;34(2), 2013 (IF 2,34)
Rapp M., Heinzel A., Galldiks N., Stoffels G., Felsberg J., Ewelt C., Sabel M., Steiger H.J, Reifenberger G., Beez T., Coenen H., Floeth F., Langen K.J.: Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions with suspicion of glioma, J Nucl Med., Feb;54(2),2013 (IF 6,38)
Rapp M., Rapp M., C. Berg C., Knoepfle G., Bartmann P., Mueller A.: Prenatal diagnosis and clinical outcome of kaposiform hemangioendothelioma in siblings, Klinische Pädiatrie Okt 6, 2012 (IF 1,77)
Abdulazim A., Zella S., Rapp, M., Gierga K., Langen K.J., Steiger H.J, Sabel M:Meningioangiomatosis in a patient with progressive focal neurological deficit- case report and review of literature, Br J Neurosurg., Nov 20,2012(IF 0,88)
Galldiks N., Rapp M., Stoffels G., Fink GR., Shah NJ., Coenen HH., Sabel M., Langen K-J. : Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F] Fluoroethyl-L-tyrosine PET in comparison to MRI, Eur J Nucl Med Mol Imaging Sept. 29, 2012(IF 4,99)
KampM., DibueM., SzelenyiA., ReicheltD.C, Felsberg J., SteigerH.J., RappM., Sabel M. Proof of principle: Supramarginal resection of cerebral metastases in eloquent brain areas, Acta NC, Nov 11, 2012(IF 1,52)
Rapp M., Klingenhöfer M., Felsberg J., Steiger H.J., Stummer W., Sabel M. Fluorescence-Guided Resection of Spinal Metastases of Malignant Glioma – Report of 2 Cases, Cen Eur Neurosurg. Mar 10, 2011(IF 0,83)
Rapp M., Felsberg J, Sorg RV, Gerharz C.D, Sabel M. Case report: extracranial metastasis from gliosarcoma – the influence of immune system,Br J Neurosurg. Dec 15, 2010(IF 0,88)
Ewelt C., Goeppert M., Rapp M., Steiger H.J., Stummer W., Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival, J Neurooncol. Oct 16, 2010(IF 2,92)
Ringelstein A, Turowski B, Gizewski ER, Schroeteler J, Rapp M.,Saleh A, Lanzman RS, Mathys C, Sabel M, Mödder U.Evaluation of ADC Mapping as an Early Predictor for Tumor Response to Chemotherapy in Recurrent Glioma Treated with Bevacizumab/Irinotecan: Proof of Principle, Rofo.Aug 25, 2010(IF 2,47)
Wick W., Hartmann C., Engel C., Stoffels M., Felsberg J., Stockhammer F., Sabel M. C., Koeppen S., Ketter R., Meyermann R., Rapp M., Meisner C., Kortmann R. D., Pietsch T., Wiestler O. D., Ernemann U., Bamberg M., Reifenberger G., von Deimling A., Weller M. NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide, J Clin Oncol, Nov 9, 2009 (IF 17,79)
Hänggi D., Eicker S., Beseoglu K., Rapp M., Perrin J., Nawatny J., Turowski B., Sommer C., Steiger H. J. Dose-related efficacy of a continuous intracisternal nimodipine treatment on cerebral vasospasm in the rat double subarachnoid hemorrhage model, Neurosurgery64(6): 1155-9, 2009(IF 2,86)
Felsberg J., Rapp M., Loeser S., Fimmers R., Stummer W., Goeppert M., Steiger H. J., Friedensdorf B., Reifenberger G., Sabel M.C Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients, Clin Cancer Res; 15(21) November 1, 2009(IF 6,74)
De Vleeschouwer S., Rapp M., Sorg R.V., SteigerH.J., Stummer W., van Gool S., Sabel M. Dendritic cell vaccination in patients with malignantgliomas: current status and future directions, Neurosurgery 59 (5), 2006(IF 4,69)
Rapp M., Özcan Z., Steiger H.J., Wernet P., Sabel M., Sorg R.V. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy, J Neurosurg 105:41–50, 2006(IF 2,36)
Schellhammer F., Rapp M., Saleh A. Melorheostose der HWS bei einem intraspinalen LipomFortschr Röntgenstr; 178: 816–823, 2006(IF 1,76)
Sabel M., Rommel F., Kondakci M., Gorol M., Willers R., Bilzer T. Locoregional Opening of the Rodent Blood–Brain Barrier for Paclitaxel Using Nd:YAG Laser-Induced Thermo Therapy: A New Concept of Adjuvant Glioma Therapy? Lasers in Surgery and Medicine 33:75–80, 2003(IF 2,74)
Sabel M., Rommel F., Kondakci M., Gorol M., Willers R., Bilzer T. Laser Induced Thermotherapy and Blood-Brain-Barrier Changes: A Review, Medical Laser Application, März 2002 (IF)
insg. 63,38 IF
10 Erstautoren- Paper (18,47IF)
21Coautoren- Paper (54,91 IF)
nach PD:
Erstautoren Paper:
Co-Shared Erstautoren: 1 (1,52 IF)
Coautoren Paper: 3 (12,77IF)
Veröffentlichte Abstracts:
Schroeteler J., Ringelstein A., Rapp M., Stoffels G., Langen K.J., Sabel M. MRI and FET-PET demonstrate early response to Bevacizumab and Irinotecan Therapy in Recurrent Malignant Glioma, Neuro-oncol 10 (5):326, 2008
Kriese Y., Rapp M., Ewelt C., Stummer W., Steiger H. J. , Sabel M. The cost of living: Quality of life in glioblastoma patients, Neuro-oncol 10 (5): 326, 2008
Rapp, M., Sabel, M., Özcan, Z., Fischer, J., Rox, J., Sorg, R. V. Immunotherapy of Glioblastoma with Autologous Dendritic Cells, Neuro-oncol 10 (5): 326, 2008
Sabel M., Loeser S., Luyken C., Willers R., Rapp M., Reifenberger G. The prognostic value of MGMT promoter hypermethylation and other genetic markers in malignant glioma patients treated with temozolomide, Neuro-oncol 8 (4): 326, 2006
Loeser S.C., Blaschke B., Köhler S., Kreuzmann A., Rapp M., Goeppert M., Reifenberger G., Sabel M. Prognostic value of MGMT methylation and expression in malignant glioma patients treated with adjuvant temozolomide chemotherapy, Acta Neuropathologica 112 (3): 375, 2006
Trampe-Kieslich A., El-Khatoutti A., Rapp M., Kögler G., Wernet P., Trapp T., Sabel M., Reifenberger G. Migration of somatic stem cells from umbilical cord blood towards glioma cells, Acta Neuropathologica 112 (3): 375, 2006
1